Regarding the updated efficacy results (data cutoff May2023), ORR was 17.2% (10/58) and CBR 29.3% (17/58). Clinical responses were observed in different cancer-types, including mesothelioma, sarcoma, carcinoma of primary unknown, cholangiocarcionoma, colorectal, ovarian, gastric and pancreatic cancers....Spartalizumab monotherapy demonstrated promising efficacy data and a favorable safety profile in heavily treated patients with immune-inflamed solid tumors expressing high levels of PD1 mRNA.